A multicentre, randomised, double-blind placebo-controlled, phase II study to evaluate the safety, tolerability and dose of dried intestinal microbiota medicinal product EBX-102 in liver cirrhosis subjects (IMPuLCE)
The liver normally cleans toxins, such as ammonia, from your blood. When someone has liver cirrhosis, scarring stops the liver from working properly. Toxins can build up and reach the brain, causing confusion, memory issues, or serious illness, a condition called hepatic encephalopathy. Doctors have found that an unhealthy balance of gut bacteria plays a major role in making liver disease worse. The IMPuLCE study is testing a potential treatment called EBX-102. EBX-102 is a capsule containing freeze-dried, healthy gut bacteria taken from carefully screened donors. In this study, adults with cirrhosis take a single dose of either EBX-102 or a dummy capsule (placebo). Doctors will then check on them over 12 weeks using simple tests, including blood tests and stool samples. The aim is to see if this treatment is safe and can improve gut health.
At a glance
What is this study about?
The liver has many vital jobs, including breaking down waste products like ammonia. In advanced liver disease, known as cirrhosis, scar tissue builds up and stops the liver from filtering blood effectively. When ammonia builds up in the body, it can travel to the brain. This can lead to hepatic encephalopathy, which causes symptoms ranging from mild confusion and sleep changes to severe drowsiness and memory problems.
Medical experts now know that the community of bacteria living in our gut (the gut microbiome) has a huge influence on liver health. In people with cirrhosis, this gut community often becomes unbalanced, producing more toxins and making infections more likely. Existing medicines, such as lactulose, help clear ammonia out through the bowels, but they do not always fix the underlying gut bacteria imbalance and can cause unpleasant stomach issues.
This trial is looking at whether a new medicine called EBX-102 can safely introduce healthy microbes into the digestive tract. EBX-102 comes in simple capsules containing dried microorganisms collected from healthy, thoroughly tested human stool donors. Researchers hope that rebuilding a balanced gut community will help reduce toxin build-up and protect the brain. The study is run through NHS Greater Glasgow and Clyde to determine safe doses and monitor participants' health over 12 weeks.
Key takeaways
- The IMPuLCE trial is testing EBX-102, a capsule of healthy donor bacteria, for people with liver cirrhosis.
- The goal is to test if repairing the gut bacterial balance safely helps prevent brain complications like confusion.
- Participants take a single dose of capsules and are monitored closely over 12 weeks.
- You will be randomly assigned to receive either the active treatment or a placebo.
- Joining is completely voluntary, and you can withdraw at any time without affecting your NHS care.
Who may be eligible?
This trial is open to adults aged 18 and older who have a confirmed medical diagnosis of liver cirrhosis. The diagnosis is typically confirmed using hospital scans (such as an ultrasound, CT scan, or FibroScan) or a liver biopsy done in the past.
Depending on which part of the study you join, your liver disease will need to be within a specific range of severity, measured by standard blood tests. If you are taking standard medicines for your liver, such as lactulose or rifaximin, your dose should be stable before you enter the study.
You cannot take regular over-the-counter probiotic pills or supplements from pharmacies during the trial, though standard supermarket foods like live yoghurts and cheese are fine. Participants must also follow clear guidelines regarding alcohol: those with an alcohol use disorder must be willing to stop drinking completely, while others must stay within standard NHS sensible drinking limits (no more than 14 units a week).
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have a confirmed diagnosis of liver cirrhosis.
- If I take lactulose or rifaximin, my dose has been stable recently.
- I am happy to pause any shop-bought probiotic supplements for 12 weeks.
- I am willing to follow trial rules on alcohol and attend clinic visits for blood and stool checks.
What does participation involve?
Taking part in this study lasts for about 12 weeks. After initial health checks to ensure the study is right for you, you will receive a single dose of capsules to swallow in the clinic under medical supervision. Because this is a randomised trial, you will be allocated by chance to receive either the active EBX-102 capsules or matching dummy capsules (placebo).
Over the next 12 weeks, you will have regular clinic follow-up appointments so the team can monitor your health. These visits will involve standard checks, including blood and urine tests, collecting stool samples, heart tracings (an ECG), simple memory and thinking tests, and questionnaires about how you feel. The study doctors will keep a close eye on you to check for any side effects and to see how your gut bacteria change over time.
Potential risks and benefits
Locations (11)
- Glasgow Royal InfirmaryApproximateGlasgow, Scotland
- King's College Hospital NHS Foundation TrustCity onlyLondon, England
- Aberdeen Royal InfirmaryApproximateAberdeen, Scotland
- North Tyneside General HospitalApproximateNorth Shields, England
- Nottingham University Hospitals NHS Trust - Queen's Medical Centre CampusCity onlyNottingham, England
- Hull University Teaching Hospitals NHS TrustUnverifiedHull, England
- Queen Elizabeth University HospitalUnverifiedGlasgow, Scotland
- Bradford Teaching Hospitals NHS Foundation TrustUnverifiedBradford, England
- University Hospitals of Leicester NHS TrustUnverifiedLeicester, England
- University Hospital Southampton NHS Foundation TrustUnverifiedSouthampton, England
- St George's University Hospitals NHS Foundation TrustUnverifiedLondon, England
Common questions
What is EBX-102 made of?
EBX-102 contains natural, healthy gut bacteria collected from human stool donors. The donors are screened very carefully to ensure they are healthy, and the samples are thoroughly tested and freeze-dried into tasteless capsules.
Will I definitely receive the new treatment?
Not necessarily. This is a double-blind, placebo-controlled study, meaning half the participants receive EBX-102 and half receive a dummy capsule (placebo). Neither you nor your study doctor will choose or know which one you receive until the trial ends.
Can I keep taking my regular liver medications?
Yes. In fact, if you take medicines like lactulose or rifaximin, the study team usually requires you to stay on a steady, stable dose throughout the trial.
Can I still eat yoghurt or fermented foods?
Yes. Everyday supermarket foods like yoghurt, cheese, and pickles are fine. You only need to avoid specialist probiotic capsules, powders, or drinks bought from pharmacies or health shops.
What happens if I feel unwell during the trial?
A safety review team closely monitors all participants. If you develop symptoms like stomach upset or fever, you should contact the study team right away. They can examine you and provide treatments to help ease your symptoms.
How to find out more
Akil Jackson
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.